Search Results (30)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. | Academic Article |
Why?
|
| Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. | Academic Article |
Why?
|
| Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. | Academic Article |
Why?
|
| Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group. | Academic Article |
Why?
|
| An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. | Academic Article |
Why?
|
| CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. | Academic Article |
Why?
|
| CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. | Academic Article |
Why?
|
| Earlier initiation of antibiotic therapy: Does prophylaxis offer greater benefit in AML? | Academic Article |
Why?
|
| Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. | Academic Article |
Why?
|
| A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. | Academic Article |
Why?
|
| Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. | Academic Article |
Why?
|
| Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. | Academic Article |
Why?
|
| CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. | Academic Article |
Why?
|
| Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. | Academic Article |
Why?
|
| Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. | Academic Article |
Why?
|